Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions
Brief Summary: This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions.

The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a medicine called deferasirox (ICL670) with another medicine called deferoxamine (DFO). The study is aimed at finding out which of the two medicines is the best for treating iron overload in the heart.

Patients will be treated for 12 months (core study phase). Patients who complete the core study phase will be offered to continue their study treatment in a 12 months extension phase. During the core and extension, the effects of treatment on iron overload in the heart and the liver will be evaluated using specific magnetic resonance imaging (MRI) assessments.


Options:
A: Arm Label: Deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Core Study: Deferasirox, Drug: Deferasirox | Arm Label: Deferasirox Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Core Study: Deferoxamine, Drug: Deferoxamine | Arm Label: Extension: deferoxamine to deferasirox; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferoxamine to deferasirox | Arm Label: Extension: deferasirox to deferoxamine; Type: EXPERIMENTAL; Interventions: Drug: Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Core Study: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Core Study: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo | Intervention Type: DRUG; Name: Extension: deferoxamine to deferasirox; Assigned to Arm(s): Extension: deferoxamine to deferasirox | Intervention Type: DRUG; Name: Extension: deferasirox to deferoxamine; Assigned to Arm(s): Extension: deferasirox to deferoxamine | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Deferasirox | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferasirox Placebo
B: Arm Label: 5 mg/kg/day deferasirox; Type: EXPERIMENTAL; Interventions: Drug: deferasirox, Drug: placebo | Arm Label: 10 mg/kg/day deferasirox; Type: EXPERIMENTAL; Interventions: Drug: deferasirox, Drug: placebo | Arm Label: 5 mg/kg/day placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 10 mg/kg/day placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: deferasirox; Assigned to Arm(s): 10 mg/kg/day deferasirox, 5 mg/kg/day deferasirox | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 10 mg/kg/day deferasirox, 10 mg/kg/day placebo, 5 mg/kg/day deferasirox, 5 mg/kg/day placebo
C: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
D: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine

Answer: A